Here is a detailed review of the largest insider transactions reported on Wednesday for U.S. equities, based on recently filed Forms 4 and other disclosure documents.
Top buys
Jewett-Cameron Trading Co. Ltd. (NASDAQ:JCTC) recorded the period's most sizable insider purchase in dollar terms. On June 29, 2026, Adam James Bradley, Melinda Hodges Bradley, AJB Capital, LLC and AJB Investment Fund II, LP together purchased 353,607 shares at a per-share price of $2.28, for a total consideration of $806,223. The filing was an amended Form 4 that clarified the number of shares beneficially owned by the reporting parties after the transaction. Those reporting owners are identified as 10% owners of Jewett-Cameron Trading Co. Ltd. Since the acquisition, the stock has traded up to $2.49, roughly 9% above the insiders' purchase price. InvestingPro data included in the filings notes a one-week return of about 13% for the shares and characterizes the company as carrying a "WEAK" financial health score with a market capitalization of approximately $8.38 million. InvestingPro's analysis also indicates the shares trade below its Fair Value estimate.
In addition to the June 29 block purchase, Adam Bradley, Melinda Bradley and entities under their control executed open-market buys of an additional 17,800 shares between June 26 and June 30, 2026. Those transactions were completed at prices between $2.21 and $2.38 per share, amounting to $42,289 in aggregate consideration. The insider buying included purchases made by Melinda Bradley's individual retirement account, which acquired 5,283 shares across three separate transactions. The stock's subsequent climb to $2.49 represents roughly a 20% increase across the one-week window cited by InvestingPro, a point the platform used to underline a perceived disconnect between current market pricing and its Fair Value estimate.
RH (NASDAQ:RH) also registered a meaningful director-level acquisition. Carlos Alberini, a member of RH's board, purchased 11,388 shares of the luxury home furnishings retailer's common stock on June 29, 2026. Those purchases were executed at prices ranging from $157.99 to $161.96 per share and had a combined value of $1,832,322. The trades were processed in multiple lots, including one block of 300 shares at a weighted average price of $158.4980 per share, a larger block of 5,502 shares at a weighted average of $160.5823 per share, and another 5,586-share tranche at a weighted average of $161.3407 per share. At the time of reporting, RH was trading at $164.05, modestly above Alberini's executed prices. InvestingPro's assessment in the filings suggests RH is trading below its Fair Value, a factor the analysts point to when contextualizing the director's decision to buy. The filings also highlight RH's price volatility: shares have fallen about 20% over the past 12 months despite trading well above a 52-week low of $106.30.
Faeth Therapeutics, Inc. (FTH) Chief Financial Officer Brian C. Stephenson reported a series of purchases of common stock. Per a Form 4 filing, Mr. Stephenson acquired 13,634 shares in multiple transactions that took place on June 29, June 30 and July 1, 2026, at prices spanning $22.95 to $24.98 per share. The cumulative cost of those purchases was $326,127. The disclosure states the purchased shares are held indirectly by the Brian Stephenson Revocable Trust, over which Mr. Stephenson is sole trustee with exclusive voting and investment authority. At the time of the filing, Faeth Therapeutics shares were trading at $23.66, after a 145% gain over the prior six months. InvestingPro commentary included in the filings notes the stock appears overvalued relative to Fair Value, while also reporting analyst price targets in the $50 to $60 range.
GitLab Inc. (NASDAQ:GTLB) Chief Executive Officer William Staples increased his stake in the company by purchasing 4,188 shares of GitLab Class A common stock on June 30, 2026. The transaction was executed at $29.36 per share for a total of $122,959 and was carried out under a Rule 10b5-1 trading plan that Mr. Staples established on September 25, 2025. Since that purchase, the stock has traded at $31.53. InvestingPro's valuation view included in the disclosure describes the company as slightly undervalued relative to its Fair Value assessment.
Top sells
Oruka Therapeutics, Inc. (NASDAQ:ORKA) saw a very large disposition tied to a conversion event. Fairmount Healthcare Fund II L.P. sold 3,553,410 shares of Oruka common stock on July 1, 2026, realizing proceeds of $300,014,406 at $84.43 per share. The filings show these common shares were issued that same day upon conversion of 42,641 shares of Series B Preferred Stock into 3,553,410 shares of common stock, and the conversion was effected for no cash consideration in accordance with the Series B terms. InvestingPro data referenced in the filings notes that Oruka's shares have surged approximately 640% over the last year and trade close to a 52-week high of $97.78, currently at $93.29. The platform additionally lists the stock among its most overvalued names.
Applied Materials Inc. (NASDAQ:AMAT) President and Chief Executive Officer Gary E. Dickerson reported sales totaling 78,321 shares across June 29 and June 30, 2026. The transactions produced proceeds in the neighborhood of $55.5 million, with executed prices ranging from $700.21 to $736.05 per share. On June 29, Mr. Dickerson sold 50,332 shares at a weighted average price reported as $700.21 per share; the sales were carried out in several transactions priced between $700.00 and $700.98. That same day he sold an additional 7,989 shares at a weighted average price of $701.33 per share, where individual trades recorded prices within $701.04 to $701.64.
Airbnb, Inc. (NASDAQ:ABNB) director and 10% owner Joseph Gebbia sold 294,903 shares of Class A common stock on June 29, 2026, in transactions totaling approximately $43.8 million. The shares were sold at prices between $145.90 and $150.0326 per share. According to InvestingPro figures cited in the filings, Airbnb was trading at $147.34 at the time, which places the market price roughly 1% below a 52-week high of $150.19. The reported sales were made indirectly by the Sycamore Trust under a Rule 10b5-1 trading plan adopted on February 27, 2026.
Snowflake Inc. (NYSE:SNOW) director Frank Slootman sold 99,900 shares of common stock for aggregate proceeds of about $25.1 million on June 29, 2026, executing the transactions under a 10b5-1 plan adopted on September 19, 2025. The reported sales were completed at varying prices between $250.000 and $254.220 per share, with weighted-average sale prices between $250.458 and $254.202 noted in the filings. On the same day Mr. Slootman exercised options to acquire 99,900 shares of common stock. Snowflake had risen roughly 15.6% over the prior week and was trading at $261.19, approaching a 52-week high of $285.
Workday, Inc. (NASDAQ:WDAY) ten percent owner David A. Duffield reported disposition of 107,500 shares of Class A common stock on June 30, 2026, for proceeds of about $13,119,166. The sales occurred at prices ranging from $119.47 to $123.4899 per share and were carried out pursuant to a Rule 10b5-1 trading plan established by the David A. Duffield Trust on December 2, 2025. InvestingPro commentary in the filings underscores that Workday shares have declined approximately 43% over the last six months, while the platform currently classifies the stock as trading below its Fair Value estimate, listing it among its most undervalued names.
Context and considerations
These filings illustrate a mix of insider motivations and market contexts. The large buy-side activity at Jewett-Cameron involved parties identified as substantial owners in the company and was memorialized in an amended Form 4 that clarified beneficial ownership. Purchases by a director at RH and the CEO of GitLab were accompanied in the filings by InvestingPro valuation commentary describing both names as trading below Fair Value. Conversely, the Faeth Therapeutics CFO executed purchases even as InvestingPro flagged the shares as currently overvalued versus Fair Value.
On the sell side, the sizeable liquidation by Fairmount Healthcare Fund II L.P. in Oruka followed a mechanical conversion of preferred shares to common stock on the same day, enabling a large block sale. Executives at larger-cap technology and industrial names also completed planned or systematic sales under Rule 10b5-1 programs or reported sales in multiple transactions, representing substantial dollar amounts and a variety of strategic or personal reasons for selling.
Bottom line - Insider transactions provide a datapoint on how company insiders and large holders are moving their shares, but these actions should be weighed alongside valuation metrics, plan-driven sale mechanics and other factors. Insider buys can reflect confidence, while sales do not necessarily indicate a lack of conviction, given the range of tax, diversification or liquidity reasons that motivate dispositions.
Key points
- Concentrated purchasing at Jewett-Cameron involved insiders and related entities acquiring 353,607 shares at $2.28 on June 29, 2026, plus additional open-market buys totaling 17,800 shares between June 26 and June 30, 2026.
- Large disposals included a conversion-driven sale of 3,553,410 Oruka Therapeutics shares by Fairmount Healthcare Fund II L.P. and multimillion-dollar sales by executives at Applied Materials, Airbnb, Snowflake and Workday.
- InvestingPro valuation commentary accompanies many filings, with several names cited as trading below Fair Value and others flagged as overvalued, providing context but not definitive investment advice.
Risks and uncertainties
- Valuation conflict - Several filings highlight disparities between insider transactions and InvestingPro Fair Value assessments, posing the risk that insider activity may not align with platform valuation signals; this affects equity valuations broadly, including small caps and technology names.
- Conversion mechanics - The Oruka transaction followed an in-day conversion of preferred stock to common shares and a subsequent large sale, demonstrating how structural conversion events can produce sudden supply and impact market pricing in a single security.
- Planned sales under 10b5-1 - Multiple large sales were conducted under pre-arranged Rule 10b5-1 plans, indicating those disposals may have been scheduled rather than opportunistic, which complicates using sales as a straightforward signal of insider sentiment; this applies especially to technology and software sectors represented in the filings.
Monitoring insider disclosures can be a useful element of investment research, but such information should be considered alongside other financial metrics, plan mechanics and company-specific fundamentals.
Note: The figures and valuation commentary above are drawn from the companies' regulatory filings and InvestingPro data included in those filings. Investors should treat insider trading information as one input among many when forming an investment view.